Black Diamond Therapeutics Inc expected to post a loss of 75  cents a share - Earnings Preview

Black Diamond Therapeutics

03/05/2022 16:44

* Black Diamond Therapeutics Inc  BDTX.OQ   BDTX.O  is
expected
to show no change in quarterly revenue when it reports 
results on May 5 (estimated). 
    * ​Refinitiv's mean analyst estimate for Black Diamond
Therapeutics Inc is for a loss of 75 cents per share. For the
same quarter last year, the company reported a loss of 84 cents
per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $6.5​, above​ its last closing price
of $2.36. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021              -1.01      -0.71     Beat    29.9
 Sep. 30 2021  -0.98       -0.98      -0.97     Beat    0.9
 Jun. 30 2021  -0.87       -0.84      -0.95     Missed  -13.1​
 Mar. 31 2021  -0.67       -0.68      -0.84     Missed  -23.7
 ​​Dec.        -0.56       -0.63      -0.63     Met     0
 31 2020                                                
 Sep. 30 2020  -0.51       -0.52      -0.50     Beat    4.6​
 Jun. 30 2020  -0.44       -0.44      -0.41     Beat    7.7
 Mar. 31 2020  -0.48       -0.48      -0.51     Missed  -5.4
 This summary was machine generated May 3 at 15:44 GMT.  All
figures in US dollars  unless otherwise stated